Emergent BioSolutions Inc. EBS announced that the Centers for Disease Control and Prevention (CDC) has exercised options under an existing contract, worth $44 million, for the supply of Vaccinia ...
Emergent BioSolutions Inc. EBS announced that it has received a contract award of approximately $535 million spread over a 10-year period for the continued delivery of Vaccinia Immune Globulin ...
The U.S. Centers for Disease Control and Prevention (CDC) has exercised contract options valued at $18.9 million over three years for Emergent BioSolutions to continue supplying Vaccinia Immune ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Emergent BioSolutions Inc. announced a contract modification with the U.S. Department of Health and Human Services to provide additional doses of its smallpox treatment, CNJ-016® (Vaccinia Immune ...
GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE)-- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® ...
The U.S. Food and Drug Administration has approved Vaccinia Immune Globulin Intravenous (VIGIV) -- the first intravenous human plasma-derived product available to treat certain rare complications of ...
With an FDA nod for its vaccinia immune globulin, DVC LLC will provide the U.S. military with a product addressing the serious side effects of the smallpox vaccine. Although smallpox was declared ...
On Wednesday, Emergent BioSolutions Inc. (NYSE:EBS) said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and mpox product portfolio. What ...
GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016 ® [Vaccinia Immune Globulin ...
Emergent BioSolutions Inc. EBS announced that it has received a contract award of approximately $535 million spread over a 10-year period for the continued delivery of Vaccinia Immune Globulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results